PL367412A1 - Mineralno-proteinowy preparat a neuropatia cukrzycowa - Google Patents

Mineralno-proteinowy preparat a neuropatia cukrzycowa

Info

Publication number: PL367412A1
Authority: PL; Poland
Prior art keywords: diabetes; insulin; neuropathy; mineral; protein preparation
Prior art date: 2001-07-06

Application number

PL02367412A

Other languages

English (en)

Other versions

PL204965B1 (pl

Inventor

Robert Basic

Mirko Hadzija

Boris Subotic

Original Assignee

Robert Basic

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-07-06

Filing date

2002-07-05

Publication date

2005-02-21

2002-07-05 Application filed by Robert Basic filed Critical Robert Basic

2005-02-21 Publication of PL367412A1 publication Critical patent/PL367412A1/pl

2010-02-26 Publication of PL204965B1 publication Critical patent/PL204965B1/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3486—Humulus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Alternative & Traditional Medicine (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Medical Informatics (AREA)
Botany (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL367412A 2001-07-06 2002-07-05 Preparat mineralno-proteinowy do zapobiegania rozwojowi neuropatii u chorych na cukrzycę PL204965B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HR20010326A HRP20010326A2 (en)	2001-07-06	2001-07-06	Mineral-protein preparations (mmp) and neuropathies in diabetes

Publications (2)

Publication Number	Publication Date
PL367412A1 true PL367412A1 (pl)	2005-02-21
PL204965B1 PL204965B1 (pl)	2010-02-26

Family

ID=10947309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL367412A PL204965B1 (pl)	2001-07-06	2002-07-05	Preparat mineralno-proteinowy do zapobiegania rozwojowi neuropatii u chorych na cukrzycę

Country Status (8)

Country	Link
US (1)	US7074437B2 (pl)
EP (1)	EP1409001B1 (pl)
AT (1)	ATE323504T1 (pl)
AU (1)	AU2002345248A1 (pl)
DE (1)	DE60210774D1 (pl)
HR (1)	HRP20010326A2 (pl)
PL (1)	PL204965B1 (pl)
WO (1)	WO2003013563A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050031708A1 (en) *	2003-08-06	2005-02-10	Portney Micah S.	Composition comprising a zeolite compound for treatment of diseases
US20090104286A1 (en) *	2005-12-29	2009-04-23	Robert Basic	Regulation of allergic reaction
CN200972926Y (zh) *	2006-11-03	2007-11-07	富士康(昆山)电脑接插件有限公司	电连接器
EP2609926B1 (en) *	2011-12-30	2013-10-23	Jakob Hraschan	Prevention or treatment of painful polyneuropathies by administration of an aluminosilicate
EP3037098B1 (en)	2014-12-22	2025-03-26	Mario Martelli	Composition for the treatment and prevention of a disorder correlated with haematic cholesterol and /or hematic glycemia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100195886B1 (ko) *	1996-11-01	1999-06-15	김상조	당뇨병 치료용 의약조성물
WO1999055351A1 (en) *	1998-04-23	1999-11-04	Vladimir Leko	Herbal composition and medicament against diabetes mellitus type ii manufactured thereof
CN1151800C (zh) *	1999-07-23	2004-06-02	王钢柱	一种治疗糖尿病周围神经病变的药物
HRP20000410B1 (hr) *	2000-06-16	2012-06-30	Ba�i� Robert	Novi inhibitor apoptoze živčanih stanica

2001
- 2001-07-06 HR HR20010326A patent/HRP20010326A2/hr not_active Application Discontinuation
2002
- 2002-07-05 AU AU2002345248A patent/AU2002345248A1/en not_active Abandoned
- 2002-07-05 AT AT02743459T patent/ATE323504T1/de not_active IP Right Cessation
- 2002-07-05 US US10/482,875 patent/US7074437B2/en not_active Expired - Fee Related
- 2002-07-05 DE DE60210774T patent/DE60210774D1/de not_active Expired - Lifetime
- 2002-07-05 PL PL367412A patent/PL204965B1/pl not_active IP Right Cessation
- 2002-07-05 WO PCT/HR2002/000034 patent/WO2003013563A2/en not_active Ceased
- 2002-07-05 EP EP02743459A patent/EP1409001B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1409001A2 (en)	2004-04-21
ATE323504T1 (de)	2006-05-15
HRP20010326A2 (en)	2003-02-28
US20040175436A1 (en)	2004-09-09
AU2002345248A1 (en)	2003-02-24
PL204965B1 (pl)	2010-02-26
US7074437B2 (en)	2006-07-11
EP1409001B1 (en)	2006-04-19
DE60210774D1 (de)	2006-05-24
WO2003013563A2 (en)	2003-02-20
WO2003013563A3 (en)	2003-04-10

Similar Documents

Publication	Publication Date	Title
Homko et al.	2003	Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects
Yang et al.	2015	Phase‐transition microneedle patches for efficient and accurate transdermal delivery of insulin
Garber et al.	2007	Premixed insulin treatment for type 2 diabetes: analogue or human?
Home et al.	1999	Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers
Home	2015	Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?
Soran et al.	2006	Insulin detemir: a new basal insulin analogue
Hildebrandt	1991	Subcutaneous absorption of insulin in insulin-dependent diabetic patients. Influence of species, physico-chemical properties of insulin and physiological factors.
Brange	1997	The new era of biotech insulin analogues
CA2196999A1 (en)	1996-12-19	Treatment of type ii diabetes mellitus with amylin agonists
JP2003501361A5 (pl)	2007-02-01
CA2373266A1 (en)	2000-12-07	Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
Liebl et al.	2013	A novel insulin combination of insulin degludec and insulin aspart achieves a more stable overnight glucose profile than insulin glargine: results from continuous glucose monitoring in a proof-of-concept trial
Marena et al.	1993	The artificial endocrine pancreas in clinical practice and research. The present position and future perspectives.
Thow et al.	1990	Different absorption of isophane (NPH) insulin from subcutaneous and intramuscular sites suggests a need to reassess recommended insulin injection technique
Nielsen et al.	1995	Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen
Geffner et al.	1983	Early-morning hyperglycemia in diabetic individuals treated with continuous subcutaneous insulin infusion
Kaku et al.	2000	Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers
Linnebjerg et al.	2006	Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes
PL367412A1 (pl)	2005-02-21	Mineralno-proteinowy preparat a neuropatia cukrzycowa
DE60032346D1 (en)	2007-01-25	Isolated islets, comprising insulin producing cells, coated with heparin
Ponte et al.	1986	Involvment of the visual evoked potentials in type I insulin-dependent diabetes
Lassmann‐Vague et al.	1996	Insulin kinetics in type I diabetic patients treated by continuous intraperitoneal insulin infusion: influence of anti‐insulin antibodies
CN106138011B (zh)	2018-12-25	碳酸钙/透明质酸复合药物载体及其制备方法
Nakamura et al.	2020	Insulin and heparin challenge tests are useful for choosing an optimal insulin regimen in a case of subcutaneous insulin resistance
Bell et al.	2004	Outcomes of initiation of therapy with once‐daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes

Legal Events

Date	Code	Title	Description
2012-09-28	LAPS	Decisions on the lapse of the protection rights	Effective date: 20110705